Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors by A. M. Malkova, R. V. Orlova, N. V. Zhukova, A. R. Gubal, V. V. Sharoiko

Get full text

Laboratory biomarkers of an effective antitumor immune response. Clinical significance. by A.M. Malkova, V.V. Sharoyko, N.V. Zhukova, A.R. Gubal, R.V. Orlova

Get full text

Clinical and epidemiological features of hemorrhagic fever with renal syndrome course in Perm region by M. V. Ivanova, N. N. Vorob’ova, K. V. Shmagel, A. M. Malkova, A. A. Kostarev

Get full text

Autoimmune component in the etiology of sarcoidosis by A. A. Starshinova, A. M. Malkova, Yu. S. Zinchenko, N. Yu. Basantsova, D. A. Kudlay, P. K. Yablonskiy

Get full text

Key differences between anti-PD-1/PD-L1 inhibitors by N. V. Zhukova, R. V. Orlova, E. A. Kaledina, P. A. Naymushina, A. M. Malkova, N. P. Beliak

Get full text

Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patient... by R. V. Orlova, N. V. Zhukova, A. M. Malkova, E. A. Kaledina, A. R. Gubal, V. V. Sharoiko

Get full text

Features of tuberculosis diagnosis in the COVID-19 by O. L. Ekaterincheva, A. M. Malkova, V. E. Karev, I. V. Kudryavtsev, Yu. S. Zinchenko, T. B. Potepun, D. A. Kudlai, A. A. Starshinova

Get full text

Limitations and opportunities of cancer treatment in the COVID-19 pandemic by R. V. Orlova, E. A. Kaledina, A. M. Malkova, N. V. Zhukova, P. A. Naymushina, N. P. Beliak, A. E. Jukova, A. S. Sarmatova, N. A. Karaseva, I. V. Egorova, K. N. Teslenko, A. V. Tarasov

Get full text